This move is archived. Current quotes and coverage live on the stock page.
Get MDP alerts:
Medexus Pharmaceuticals Inc is experiencing a notable decline in its stock price, closing down 4.55% today.
In the latest trading session, Medexus Pharmaceuticals Inc (MDP.TO) saw its stock price drop to CA$3.99, marking a significant decrease of 4.55%. This decline raises questions about the company's current market position and future prospects, especially since there hasn't been any recent news to explain the downturn.
Investor takeaway: Investors should stay alert as Medexus faces a tough market environment, with no updates to clarify its performance.
Advertisement
Medexus Pharmaceuticals Inc
MDP.TO
MDP.TO
Medexus Pharmaceuticals Inc
WealthAwesomeMarket cap
$159.64M
52W high
$5.50
52W low
$2.51
1W change
-1.76%
Beta
1.83
Analyst Price Targets
Based on analyst covering MDP
Wall Street analysts forecast MDP stock price to rise 44.7% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$7.25
+44.7% Upside
Current Price
C$5.01
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MDP's historical volatility
30-Day Vol
31.5%
Annualized
90-Day Vol
39.6%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$5.99
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$5.32 | C$4.77 โ C$5.93 |
| 60 trading days | C$5.64 | C$4.84 โ C$6.58 |
| 90 trading days | C$5.99 | C$4.96 โ C$7.23 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
4.55% Decline in Stock Price
Medexus Pharmaceuticals Inc's stock has dropped to CA$3.99, reflecting investor concerns amid a lack of recent positive developments.
Bull case
Despite todayโs decline, Medexus has potential with its GRAFAPEX product, which has previously driven strong performance this year.
Bear case
The absence of recent positive news and a negative profit margin of -0.0027 could signal underlying issues that investors should consider before making decisions.
Market Performance Overview
Advertisement
Today, Medexus Pharmaceuticals Inc's stock closed at CA$3.99, down 4.55%. This decline is significant as it comes without any recent press releases or updates from the company that might explain the drop. Investors may want to view this lack of communication as a potential red flag.
Understanding the Decline
The absence of recent news or updates regarding Medexus's product performance or strategic initiatives could be contributing to investor uncertainty. With a market cap of approximately CA$129.5 million and a negative profit margin, the company's financial health is under scrutiny. Investors should assess whether this decline is a temporary setback or indicative of deeper issues.
Looking Ahead
As Medexus Pharmaceuticals navigates this challenging period, investors should keep an eye on upcoming earnings reports and any announcements regarding product developments or partnerships. For more detailed insights into Medexus's stock performance, visit the Medexus Pharmaceuticals stock page.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile โโ Reviewed by Certified Financial Professionals
This content has been reviewed by CFAยฎ charterholders and Certified Financial Planners (CFPยฎ) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFAยฎ charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFPยฎ professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
โ ๏ธ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
